Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Peritumoral lymphatic vessel invasion compared with DNA ploidy, proliferative activity, and other pathologic features as prognostic indicators in operable breast cancer

  • 13 Accesses

  • 10 Citations

Summary

In 164 breast carcinomas the presence of peritumoral lymphatic vessel invasion (PLVI) was evaluated and correlated with other known indicators of prognosis and with the clinical outcome of the patients. Overall 22% of tumors were PLVI-positive. The presence of PLVI was significantly associated with axillary node involvement (p<0.0001) and tumor size (p=0.005), and tended toward an association with grading (p=0.065). No significant association was found between PLVI and steroid hormone receptors, DNA ploidy, or proliferative activity. Univariate analysis shows that peritumoral vessel invasion was significantly associated with a higher risk of recurrence (p=0.012) and with a trend toward shorter survival (p=0.074). Besides the presence of PLVI, prognosis was significantly worse also for patients with high proliferative aneuploid tumors and with axillary node metastases. Moreover, within the subsets of patients generally considered to have good prognosis, the presence of PLVI identified patients with a trend for higher risk such as those with PLVI-positive diploid tumors, PLVI-positive low-proliferative tumors, and PLVI-positive node-negative tumors. Adopting multivariate analysis, PLVI failed to retain prognostic importance when adjusted for node status, DNA ploidy, and proliferative activity.

In conclusion, we found that the presence of PLVI has prognostic significance when singly evaluated. Multivariate analysis shows that PLVI is not an independent prognostic factor in stage I–II breast cancer.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Friedell GH, Betts A, Sommers TC: The prognostic value of blood vessel invasion and lymphocytic infiltrates in breast carcinoma. Cancer 18: 164–166, 1965

  2. 2.

    Rosen PP, Saigo PE, Braun DW Jr,et al.: Predictors of recurrence in Stage I (T1NoMo) breast carcinoma. Ann Surg 193: 15–25, 1981

  3. 3.

    Dawson PJ, Ferguson DJ, Karrison T: The pathological findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer 50: 2131–2138, 1982

  4. 4.

    Nealon TFJ, Nkongho A, Grossi CE,et al.: Treatment of early cancer of the breast (T1NoMo and T2NoMo) on the basis of histologic characteristics. Surgery 89: 279–289, 1981

  5. 5.

    Bettelheim R, Penham HG, Thornton-Jones H,et al.: Prognostic significance of peritumoral vascular invasion in breast cancer. Br J Cancer 50: 771–777, 1984

  6. 6.

    Van de Velde CJ, Gallager HS, Giacco GC: Prognosis in nodenegative breast cancer. Breast Cancer Res Treat 8: 189–196, 1986

  7. 7.

    Lee AK, De Lellis RA, Silverman ML,et al.: Lymphatic and blood vessel invasion in breast carcinoma: a useful prognostic indicator? Human Pathol 17: 984–987, 1986

  8. 8.

    Sampat MB, Sirsat MV, Gandadharan P: Prognostic significance of blood vessel invasion in carcinoma of the breast in women. J Surg Oncol 9: 623–632, 1977

  9. 9.

    Weigand RA, Isenberg WM, Russo J,et al.: Blood vessel invasion and axillary lymph node involvement as prognostic indicators for human breast cancer. Cancer 50: 962–969, 1982

  10. 10.

    Davis BW, Gelber R, Goldhirsch A,et al.: Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastases. Hum Pathol 16: 1212–1218, 1985

  11. 11.

    Sears HF, Janus C, Levy W,et al.: Breast cancer without axillary metastases: are there high-risk biological subpopulations? Cancer 50: 1820–1827, 1982

  12. 12.

    Fisher ER, Sass R, Fisher B: Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers, X (protocol no 4). Discriminants for tenth year treatment failure. Cancer 53 (Suppl 3): 712–713, 1984

  13. 13.

    Bilik R, Mor C, Wolloch Y,et al.: Histopathologic high risk factors influencing the prognosis of patients with early breast cancer (T1NoMo). Am J Surg 151: 460–464, 1986

  14. 14.

    Gilchrist KW, Gould VE, Hirschl S,et al.: Interobserver variation in the identification of breast carcinoma in intramammary lymphatics. Hum Pathol 13: 170–172, 1982

  15. 15.

    Ordonez NG, Brooks T, Thomson S, Batsakis JG: Use of Ulex europaeus agglutinin I in the identification of lymphatic and blood vessel invasion in previously stained microscopic slides. Am J Surg Pathol 11: 543–550, 1987

  16. 16.

    Lee AK, De Lellis RA, Rosen PP,et al.: ABH blood group isoantigen expression in breast carcinomas: an immunohistochemical evaluation using monoclonal antibodies. Am J Clin Pathol 83: 308–319, 1985

  17. 17.

    Lee AK, De Lellis RA, Silverman ML, Heatley GJ, Wolfe HJ: Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 8: 1457–1465, 1990

  18. 18.

    Office of Medical Applications of Research, National Institutes of Health, Bethesda, MD: Consensus conference-adjuvant chemotherapy for breast cancer. JAMA 254: 3461–3463, 1985

  19. 19.

    Fisher ER, Gregorio RM, Fisher B: The pathology of invasive breast cancer: a syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no 4). Cancer 36: 1–85, 1975

  20. 20.

    Page DL, Anderson TJ: Vessel invasion. In: Page DL, Anderson TJ (eds) Diagnostic Histopathology of the Breast. Churchill Livingstone, Edinburgh, 1987, pp 283–284

  21. 21.

    Bloom HJG, Richardson WW: Histological grading and prognosis. Br J Cancer 11: 359–377, 1957

  22. 22.

    EORTC Breast Cancer Cooperative Group: Standards for the assessment of estrogen receptor in human breast cancer. Eur J Cancer 9: 379–381, 1973

  23. 23.

    Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 609–672, 1949

  24. 24.

    Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Method for analysis of cellular DNA content of paraffinembedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333–1335, 1983

  25. 25.

    Gasparini G, Reitano M, Bevilacqua P, Meli S, Pozza F, Santini G: Relationship of the epidermal growth factor receptor with the growth fraction (Ki-67 antibody) and the flow cytometric S-phase as cell kinetics parameters, in human mammary carcinomas. Anticancer Res 11: 1597–1604, 1991

  26. 26.

    Baisch H, Gohde W, Linden WA: Analysis of PCP-data to determine the fraction of cells in the various phases of the cell cycle. Radiat Environ Biophys 12: 31–39, 1975

  27. 27.

    Kaplan EL, Meyer P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

  28. 28.

    Bennett S: Log-logistic regression models for survival data. Appl Statist 32: 165–171, 1983

  29. 29.

    Gore SM, Pocock SJ, Kerr GR: Regression models and nonproportional hazards in the analysis of breast cancer survival. Appl Statist 33: 176–195, 1984

  30. 30.

    Mezzanotte G, Boracchi P, Marubini E: Analisi della sopravvivenza a lungo termine nel carcinoma mammario. Rivista di Statistica Applicata 20: 251–267, 1987

  31. 31.

    Cox DR, Hinkley DV: Theoretical Statistics. Chapman and Hall, London, 1974, pp 314–317

  32. 32.

    Hutter RVP: The role of the pathologist in breast cancer management. Cancer 66: 1363–1372, 1990

  33. 33.

    Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56: 1982–1987, 1985

  34. 34.

    Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627–633, 1989

  35. 35.

    Sigurdsson H, Baldetorp B, Borg A,et al.: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322: 1045–1053, 1990

  36. 36.

    Nicholson S, Sainsbury JRC, Holcrow P,et al.: Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node-negative subgroup. Br J Cancer 63: 146–151, 1991

  37. 37.

    McGuire WL: Breast cancer prognostic factors: evaluation guidelines. JNCI 83: 154–155, 1991

  38. 38.

    Holland R, Verbeek ALM: Prognostic assessment in node-negative breast cancer patients. J Clin Oncol 8: 1451–1453, 1990

Download references

Author information

Correspondence to Giampietro Gasparini.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gasparini, G., Meli, S., Panizzoni, G.A. et al. Peritumoral lymphatic vessel invasion compared with DNA ploidy, proliferative activity, and other pathologic features as prognostic indicators in operable breast cancer. Breast Cancer Res Tr 20, 195–204 (1991). https://doi.org/10.1007/BF01834625

Download citation

Key words

  • breast cancer
  • peritumoral lymphatic invasion
  • prognosis